Security key
18978H508
CNS Pharmaceuticals, Inc. - Common Stock (CNSP)
CUSIP: 18978H508
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 124,237
- Total 13F value
- $652,245
- Share change
- +99,621
- SEC-reported price per share
- $5.25
- Number of holders
- 9
- Value change
- +$522,895
- Number of buys
- 4
- Number of sells
- 3
- Shares outstanding
- 1,614,040
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
9
Top holders
9
CNSP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
CNS Pharmaceuticals, Inc. SEC filings
CNS Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 18978H508
Recent filing periods:
Ownership snapshot
Top reported holders of CNSP - CNS Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ikarian Capital, LLC
Disclosed value leader
Waldemar Priebe
Comparable rows
10/15
Latest evidence
31 Dec 2025
13D/G
13F
3/4/5
Lead comparable stake: 5.7%
5 rows are not safely comparable across share classes.
13D/G row: Ikarian Capital, LLC
Showing 1-6 of 15 holder rows.
Quick read
Ikarian Capital, LLC leads the comparable SEC ownership view at 5.7%.
10 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ikarian Capital, LLC's linked filing trail.
Comparable ownership
Top 5
Ikarian Capital, LLC
5.7%
ARMISTICE CAPITAL, LLC
5%
DRW Securities, LLC
0.87%
UBS Group AG
0.65%
MORGAN STANLEY
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ikarian Capital, LLC |
13D/G
|
5.7%
|
$118,700
45,830 shares
|
$0 | 31 Dec 2025 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$5,432
30,177 shares
|
-$95,575 | 30 Sep 2025 |
| DRW Securities, LLC |
13F
Company
|
0.87%
|
$126,450
14,050 shares
|
— | 30 Sep 2025 |
| UBS Group AG |
13F
Company
|
0.65%
|
$94,680
10,520 shares
|
— | 30 Sep 2025 |
| MORGAN STANLEY |
13F
Company
|
0%
|
$252
28 shares
|
— | 30 Sep 2025 |
| BARRETT & COMPANY, INC. |
13F
Company
|
0%
|
$72
8 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
9
Shares
124,237
Rows available
9
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
8
Q4 2025 holders
9
Holder diff
1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend